Sen. Sheldon Whitehouse Sells Amgen Inc. (NASDAQ:AMGN) Stock

Posted by Jeff Wilder on Sep 5th, 2026

Senator Sheldon Whitehouse (Democratic-Rhode Island) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 02nd, the Senator disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 12th.

Senator Sheldon Whitehouse also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/13/2026.
Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 8/13/2026.
Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 7/20/2026.
Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 6/30/2026.
Sold $1,001 – $15,000 in shares of Crown Castle (NYSE:CCI) on 6/25/2026.
Purchased $15,001 – $50,000 in shares of Coherent (NYSE:COHR) on 6/25/2026.
Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 6/25/2026.
Sold $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 6/24/2026.

Amgen Stock Down 1.6%

AMGN stock traded down $6.89 during midday trading on Friday, hitting $437.23. The company’s stock had a trading volume of 1,634,567 shares, compared to its average volume of 2,246,300. The firm’s 50-day moving average is $397.39 and its 200-day moving average is $367.15. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $447.03. The company has a market cap of $236.38 billion, a PE ratio of 27.17, a P/E/G ratio of 3.20 and a beta of 0.43.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.97 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on AMGN shares. Cantor Fitzgerald boosted their target price on Amgen from $350.00 to $400.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Scotiabank lifted their price target on shares of Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Morgan Stanley reissued an “overweight” rating and set a $362.00 price objective on shares of Amgen in a report on Wednesday, August 19th. Royal Bank Of Canada increased their price objective on shares of Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Finally, Mizuho raised their target price on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $381.68.

Check Out Our Latest Stock Report on AMGN

Hedge Funds Weigh In On Amgen

A number of institutional investors and hedge funds have recently made changes to their positions in AMGN. California State Teachers Retirement System increased its holdings in Amgen by 36,047.1% during the second quarter. California State Teachers Retirement System now owns 298,255,793 shares of the medical research company’s stock valued at $108,004,388,000 after buying an additional 297,430,677 shares during the last quarter. Norges Bank bought a new position in Amgen in the fourth quarter worth approximately $2,164,162,000. Bank of America Corp DE purchased a new position in shares of Amgen during the 2nd quarter worth $1,831,903,000. Capital World Investors grew its position in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Amgen by 1,102.7% during the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after acquiring an additional 2,514,254 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

About Senator Whitehouse

Sheldon Whitehouse (Democratic Party) is a member of the U.S. Senate from Rhode Island. He assumed office on January 3, 2007. His current term ends on January 3, 2031.

Whitehouse (Democratic Party) ran for re-election to the U.S. Senate to represent Rhode Island. He won in the general election on November 5, 2024.

About Amgen

(Get Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.